8-K: Omeros Corporation Reports Q3 2024 Financial Results and Provides Clinical Program Updates

Omeros Corporation announced its third quarter 2024 financial results, highlighting a reduced net loss compared to the previous year and progress in its clinical development programs.

Summary

• Omeros Corporation reported a net loss of $32.2 million, or $0.56 per share, for the third quarter of 2024, an improvement from a net loss of $37.8 million, or $0.60 per share, in the same quarter of 2023.
• The net loss for the first nine months of 2024 was $125.5 million, or $2.15 per share, compared to a net loss of $108.8 million, or $1.73 per share, for the same period in 2023.
• As of September 30, 2024, the company had $123.2 million in cash and short-term investments, a decrease of $48.7 million from December 31, 2023.
• The company incurred an $18.4 million charge related to the delivery of narsoplimab drug substance, a $21.2 million payment for term loan-related debt repurchase, and $1.9 million in term loan-related transaction costs during the year.
• Omeros is preparing to resubmit its Biologics License Application (BLA) for narsoplimab in TA-TMA following a productive meeting with the FDA and expects to submit a European marketing authorization application (MAA) in the first half of 2025.
• The company's zaltenibart program is advancing rapidly, with Phase 3 enrollment for PNH expected in early 2025 and Phase 3 initiation for C3G targeted for the first half of 2025.
• Omeros earned $9.3 million in OMIDRIA royalties on Rayner's U.S. net sales of $31.0 million in the third quarter of 2024, compared to $10.0 million on $33.3 million in sales in the same quarter of 2023.
• Total operating expenses for the third quarter of 2024 were $35.4 million, down from $48.2 million in the third quarter of 2023, primarily due to decreased clinical expenditures and employee compensation expenses.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the reduced net loss, progress in clinical programs, and clear paths to Phase 3 trials. However, the decrease in cash and the lack of guaranteed FDA approval temper the optimism.

Positives

• The company's net loss decreased in the third quarter of 2024 compared to the same period in 2023.
• Omeros has made progress in its clinical development programs, particularly with narsoplimab and zaltenibart.
• The company has a clear path to opening Phase 3 enrollment for zaltenibart in PNH.
• Omeros received rare pediatric disease designation for zaltenibart in C3G, which could lead to a priority review voucher.
• The company's operating expenses decreased year-over-year.

Negatives

• The company's cash and short-term investments decreased by $48.7 million since the end of 2023.
• Omeros incurred significant charges related to narsoplimab drug substance delivery and debt repurchase.
• The company's net loss for the first nine months of 2024 increased compared to the same period in 2023.
• OMIDRIA royalties decreased in the third quarter of 2024 compared to the same period in 2023.

Risks

• There is no guarantee that the FDA will approve narsoplimab for TA-TMA, even if the efficacy analysis results are favorable.
• The company's financial condition and results of operations could be impacted by regulatory processes and oversight.
• Challenges associated with the manufacture or supply of products could affect clinical trials and commercial sales.
• Changes in reimbursement and payment policies could impact the company's revenue.
• The company faces risks related to intellectual property claims, competitive developments, and litigation.

Future Outlook

Omeros anticipates resubmitting its BLA for narsoplimab in TA-TMA, submitting a European MAA for narsoplimab in the first half of 2025, initiating Phase 3 enrollment for zaltenibart in PNH in early 2025, and initiating Phase 3 for C3G in the first half of 2025. The company also plans to advance its other clinical programs and oncology platform.

Management Comments

• We expect that our September presubmission meeting with FDA and the minor revisions requested and incorporated in our analysis plan should clear the way to resubmit our BLA for narsoplimab in TA-TMA, said Gregory A. Demopulos, M.D., Omeros chairman and chief executive officer.
• While driving toward BLA and MAA submissions and preparing for the market launch of narsoplimab, we have also made tremendous progress in our other clinical development programs.
• For zaltenibart with strong and growing physician support successful end-of-Phase-2 meetings with both FDA and European regulators together with the manufacturing of sufficient drug supply enable us to advance directly into Phase 3 PNH enrollment, planned for early 2025, with C3G Phase 3 initiation targeted to follow soon thereafter.

Industry Context

This announcement reflects the ongoing challenges and progress in the biopharmaceutical industry, particularly in the development of treatments for rare diseases. Omeros is competing with other companies developing complement inhibitors and therapies for similar indications. The company's focus on multiple clinical programs and its oncology platform positions it for potential growth in the future.

Comparison to Industry Standards

• Omeros' reported net loss of $32.2 million for Q3 2024 is an improvement compared to its own Q3 2023 results, but it is important to compare this to other biotech companies in similar stages of development.
• Companies like Alexion Pharmaceuticals (now part of AstraZeneca) and BioMarin Pharmaceutical are established players in the rare disease space, and their financial performance and clinical trial progress serve as benchmarks.
• Omeros' progress with zaltenibart in PNH and C3G is comparable to other companies developing alternative pathway inhibitors, such as Apellis Pharmaceuticals with its pegcetacoplan.
• The company's cash position of $123.2 million is a critical metric, and it should be compared to the cash burn rates of similar companies to assess its runway.
• The OMIDRIA royalty revenue is a key source of income for Omeros, and its performance should be compared to other companies with similar royalty streams.

Stakeholder Impact

• Shareholders may be encouraged by the reduced net loss and progress in clinical programs, but concerned about the decrease in cash.
• Employees may be affected by changes in compensation expenses.
• Patients with TA-TMA, PNH, and C3G may benefit from the potential approval of narsoplimab and zaltenibart.
• Suppliers and creditors may be impacted by the company's financial performance.

Next Steps

• Omeros will proceed with conducting the primary and secondary efficacy analyses for narsoplimab in TA-TMA.
• The company will finalize and resubmit its BLA for narsoplimab as soon as possible if the analysis results are favorable.
• Omeros will submit the European MAA for narsoplimab in TA-TMA in the first half of 2025.
• Phase 3 enrollment for zaltenibart in PNH is expected to begin in early 2025.
• The company will initiate the Phase 3 program for C3G in the first half of 2025.
• Omeros will initiate a randomized, placebo-controlled, inpatient clinical study evaluating the safety and effectiveness of OMS527 in patients with CUD next year.

Key Dates

Keywords

narsoplimab, zaltenibart, TA-TMA, PNH, C3G, MASP-2, MASP-3, FDA, BLA, MAA, clinical trials, OMIDRIA, rare pediatric disease, oncology, addiction